A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A pharmacoeconomic evaluation of pharmaceutical treatment options for prostate cancer

Published:2021-06-02 Issue:13 Volume:22 Page:1685-1728
ISSN:1465-6566
Container-title:Expert Opinion on Pharmacotherapy
language:en
Short-container-title:Expert Opinion on Pharmacotherapy

Author:

Moussa Mohamad¹,Papatsoris Athanasios²,Sryropoulou Despoina³,Chakra Mohamed Abou¹,Dellis Athanasios²⁴,Tzelves Lazaros²

Affiliation:

1. Department of Urology, Al Zahraa Hospital, University Medical Center, Lebanese University, Beirut, Lebanon

2. 2nd Department of Urology, School of Medicine, Sismanoglio Hospital, National and Kapodistrian University of Athens, Athens, Greece

3. Department of Radiation Oncology, University of Patras, Patras, Greece

4. Department of Surgery, School of Medicine, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece

Funder

not funded

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14656566.2021.1925647

Reference91 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. The cost of prostate cancer care to society and to patients in the United States.

3. Characterising the castration-resistant prostate cancer population: a systematic review

4. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

5. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research Progress of PD-1/PD-L1 Inhibitors in Immunotherapy of Prostate Cancer;Advances in Clinical Medicine;2023

2. Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019;International Journal of Cancer;2022-07-07

3. Amygdalin Exerts Antitumor Activity in Taxane-Resistant Prostate Cancer Cells;Cancers;2022-06-24

4. Prostate cancer immunotherapy;Expert Opinion on Biological Therapy;2022-01-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3